Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP

Key Points

• Hudson Bay Capital Management increased its stake in Cytokinetics by 15.4% to 182,131 shares (about $10.01M), representing roughly 0.15% of the company.
• Analyst upgrades and institutional accumulation are supporting the stock: Millennium Management massively boosted its holding (+361.9%), and multiple firms raised targets (e.g., Mizuho to $100, JPMorgan to $75, HC Wainwright to $136), leaving a consensus "Moderate Buy" and an average price target near $89.89.
• Notable insider selling has occurred recently — CEO Robert Blum sold 36,601 shares (about $2.27M) and insiders have sold ~159,663 shares (~$9.94M) in the last 90 days, which could exert short‑term pressure despite positive analyst sentiment.

Hudson Bay Capital Management LP lifted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 15.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 182,131 shares of the biopharmaceutical company's stock after acquiring an additional 24,345 shares during the quarter. Hudson Bay Capital Management LP owned 0.15% of Cytokinetics worth $10,010,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of CYTK. Millennium Management LLC increased its stake in Cytokinetics by 361.9% in the 1st quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company's stock valued at $11,571,000 after purchasing an additional 225,576 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Cytokinetics by 21.2% during the second quarter. Envestnet Asset Management Inc. now owns 29,467 shares of the biopharmaceutical company's stock worth $974,000 after purchasing an additional 5,146 shares in the last quarter. Geode Capital Management LLC grew its holdings in Cytokinetics by 1.9% in the second quarter. Geode Capital Management LLC now owns 2,994,445 shares of the biopharmaceutical company's stock valued at $98,948,000 after purchasing an additional 56,961 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in Cytokinetics by 5.3% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 26,231 shares of the biopharmaceutical company's stock valued at $867,000 after purchasing an additional 1,320 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Cytokinetics by 8.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 30,684 shares of the biopharmaceutical company's stock valued at $1,014,000 after buying an additional 2,474 shares in the last quarter.

Cytokinetics Stock Up 1.2%

NASDAQ:CYTK opened at $62.95 on Friday. The company has a market cap of $7.75 billion, a P/E ratio of -9.64 and a beta of 0.56. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The firm's 50 day moving average is $63.79 and its two-hundred day moving average is $60.95.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. The firm's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the company earned ($1.26) earnings per share. Research analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Insider Transactions at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 36,601 shares of the business's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the completion of the sale, the chief executive officer owned 430,330 shares of the company's stock, valued at approximately $26,745,009.50. The trade was a 7.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Fady Ibraham Malik sold 12,033 shares of the company's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $747,850.95. Following the sale, the executive vice president owned 153,902 shares of the company's stock, valued at $9,565,009.30. This represents a 7.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 159,663 shares of company stock valued at $9,944,292 in the last ninety days. Company insiders own 2.70% of the company's stock.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target to $100 and kept an "outperform" rating, implying meaningful upside vs. the current share price — a catalyst for momentum buying. Mizuho raises target to $100
• Positive Sentiment: JPMorgan raised its target to $75 and maintained an overweight stance, adding institutional analyst support that can attract fund flows. JPMorgan raises target to $75
• Positive Sentiment: Large institutional holders (e.g., Vanguard, State Street) have been increasing positions, which supports longer‑term demand and underpins current price strength. Institutional holdings update
• Neutral Sentiment: Cytokinetics granted inducement awards (8,628 options and 5,719 RSUs) to five new hires under Nasdaq Rule 5635(c)(4); standard hiring comp — modest future dilution but intended to secure talent. Inducement grants
• Neutral Sentiment: Latest quarter showed a slight EPS miss but a revenue beat — mixed fundamentals that appear secondary to the recent analyst target moves in driving sentiment. Earnings recap
• Neutral Sentiment: Reported short‑interest data for March appears inconsistent/empty and is not a clear near‑term signal (days‑to‑cover shown as 0.0), so treat that item as noise until clarified by exchanges.
• Negative Sentiment: Significant insider selling: CEO Robert Blum sold ~36,601 shares (~$2.27M) and multiple EVPs sold large blocks across March. Large, clustered insider disposals can create short‑term selling pressure or be interpreted as diversification — worth monitoring for follow‑through. Insider selling details

Analyst Ratings Changes

Several equities research analysts recently commented on CYTK shares. HC Wainwright boosted their price objective on shares of Cytokinetics from $120.00 to $136.00 and gave the stock a "buy" rating in a research report on Monday, December 22nd. Needham & Company LLC lifted their target price on shares of Cytokinetics from $84.00 to $85.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Morgan Stanley set a $90.00 price target on shares of Cytokinetics in a report on Thursday, January 8th. Jefferies Financial Group reiterated a "buy" rating and issued a $90.00 price target on shares of Cytokinetics in a research report on Friday, January 9th. Finally, Barclays assumed coverage on shares of Cytokinetics in a research note on Wednesday, January 28th. They set an "overweight" rating and a $87.00 price objective for the company. Seventeen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $89.89.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.